Susquehanna Fundamental Investments’s iTeos Therapeutics ITOS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-66,779	Closed	-$666K	–	670
2025 Q2	$666K	Sell	66,779 -17,723	-21%	-$143K	0.02%	508
2025 Q1	$504K	Buy	+84,502	New	+$620K	0.01%	838
2022 Q1	$577K	Sell	17,930 -1,170	-6%	-$42.5K	0.01%	1018
2021 Q4	$889K	Buy	19,100 +8,010	+72%	+$267K	0.02%	699
2021 Q3	$299K	Buy	+11,090	New	+$290K	0.01%	1408
2021 Q1	–	Sell	-9,935	Closed	-$336K	–	1575
2020 Q4	$336K	Sell	9,935 -3,769	-28%	-$99.8K	0.01%	1236
2020 Q3	$338K	Buy	+13,704	New	+$369K	0.01%	1016

Other funds holding ITOS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna Fundamental Investments's ITOS Position: Q3 2025 in Review

Susquehanna Fundamental Investments sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 66,779 shares — an estimated $666K sold.

Susquehanna Fundamental Investments first reported a position in ITOS in Q3 2020 and held it in 7 quarters. The position peaked at $889K in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

Susquehanna Fundamental Investments reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 66,779 iTeos Therapeutics shares in Q3 2025, an estimated $666K.
Susquehanna Fundamental Investments first reported a position in iTeos Therapeutics in Q3 2020 and held it in 7 quarters.
Susquehanna Fundamental Investments's iTeos Therapeutics position peaked at $889K in Q4 2021.
1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2025, filed 14 Nov 2025.